[Report: dose banding and dose rounding of antineoplastic agents]

Gilbert S
Record ID 32018000911
French
Original Title: Avis: standardisation (banding) et arrondissement (rounding) des doses d’agents antinéoplasiques
Authors' objectives: Sizeable losses of antineoplastic agents intended for parenteral administration have been observed. These losses are largely attributed to unusable quantities of excess agent in partially used vials and unadministered preparations that are returned and not attributed to other patients. INESSS was mandated by the Direction générale de cancérologie of the Ministère de la Santé et des Services sociaux to assess whether Québec’s health institutions should apply the principles of dose banding and dose rounding to antineoplastic agents intended for parenteral administration to adult cancer patients and, if so, to determine the terms and procedures for application and implementation.
Authors' results and conclusions: RESULTS: The results of the systematic review of the effects of dose banding and dose rounding of antineoplastic agents revealed limited evidence for the majority of the outcomes evaluated, including the efficacy and safety of treatments. More specifically, the data suggest that dose banding could reduce the preparation time for antineoplastic agents (low level of scientific evidence). For dose rounding, the data suggest that the principles could reduce wastage of antineoplastic agents (low level of scientific evidence) and acquisition costs (moderate level of scientific evidence). In spite of the limited evidence on the topic, the stakeholders consulted believe that a variation of ± 5% between the dose administered to a patient and the calculated dose should not affect the efficacy or safety of treatment. This opinion is based on complementary information, such as inter-individual variation, National Cancer Institute assessment criteria and current tolerance in the network. It was determined from the data triangulation that there is a single documented advantage to adopting the dose banding principle: reduced preparation time. Given the lack of pertinent data on antineoplastic agent wastage, the variation in the number of preparations and treatment types between Québec health care facilities and the potentially substantial treatment procedure reorganization required to adopt this principle, this single advantage does not constitute sufficient reason to recommend the adoption of dose banding for antineoplastic agents in all Québec health care facilities. However, the application of dose rounding principle, which would require only a minor reorganization of the treatment procedure, could result in a reduction of antineoplastic agent wastage and acquisition costs. Therefore, the data triangulation supports the possibility of applying this principle in all Québec health care facilities, regardless of their disparities.
Authors' recomendations: The recommendations in this notice should help to standardize practices pertaining to the preparation of antineoplastic agents, promote the reduction of agent wastage and optimize the treatment procedure, without compromising patient quality of life or treatment efficacy. The recommendations formulated within the scope of this mandate are presented on pages 36 and 37 of this notice.
Authors' methods: To fulfill this mandate, 24 assessment questions were identified using the multi criterion CREDIS grid. The methodology used to answer these questions relied on the triangulation of three types of data: 1 – scientific data, obtained through a systematic review of scientific literature and good clinical practice guides; 2 – experiential knowledge gathered primarily from health professionals: representatives from professional orders, associations, organizations and federations and from patients; and 3 – contextual information sourced mainly from questionnaires completed by oncology care providers: pharmacy department heads and members of the Association des médecins hématologues et oncologues du Québec. The data were compiled in the CREDIS multi-criterion grid, which served as an analytical framework, data collection tool and validation tool. The grid was used to formulate recommendations through a deliberative process that considered the full spectrum of criteria reflecting a range of worldviews and the associated ethical aspects. Only those recommendations that were supported by more than 80% of consultation committee members were retained.
Details
Project Status: Completed
Year Published: 2019
Requestor: Minister of Health
English language abstract: An English language summary is available
Publication Type: Full HTA
Country: Canada
Province: Quebec
MeSH Terms
  • Antineoplastic Agents
  • Drug Costs
  • Cost Control
  • Cost Savings
Keywords
  • Cancer drugs
Contact
Organisation Name: Institut national d'excellence en sante et en services sociaux
Contact Address: L'Institut national d'excellence en sante et en services sociaux (INESSS) , 2021, avenue Union, bureau 10.083, Montreal, Quebec, Canada, H3A 2S9;Tel: 1+514-873-2563, Fax: 1+514-873-1369
Contact Name: demande@inesss.qc.ca
Contact Email: demande@inesss.qc.ca
Copyright: Gouvernement du Québec
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.